Back to top
more

Teva Pharmaceutical Industries (TEVA)

(Delayed Data from NYSE)

$18.45 USD

18.45
7,100,133

+0.01 (0.05%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $18.45 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 20% (49 out of 250)

Industry: Medical - Generic Drugs

Better trading starts here.

Zacks News

Amgen (AMGN) Q2 Earnings & Sales Beat, New Drugs Shine

Amgen (AMGN) beats estimates for earnings and sales in the second quarter. Higher demand for new growth drivers was offset by the erosion of mature brands from brand/biosimilar competition.

Teva Pharmaceutical Industries Ltd. (TEVA) Gains As Market Dips: What You Should Know

Teva Pharmaceutical Industries Ltd. (TEVA) closed at $7.91 in the latest trading session, marking a +0.64% move from the prior day.

Lilly (LLY) Q2 Earnings Beat, New Drugs Drive Sales, Stock Up

Eli Lilly's (LLY) Q2 earnings beat estimates while sales miss. New drugs drive sales despite generic competition to key drug Cialis.

Mylan (MYL) Beats on Q2 Earnings, Inks Deal with Pfizer

Mylan (MYL) gains from merger deal with a Pfizer unit and tops on earnings and sales in Q2.

Teva Pharmaceutical Industries Ltd. (TEVA) Stock Sinks As Market Gains: What You Should Know

Teva Pharmaceutical Industries Ltd. (TEVA) closed the most recent trading day at $7.68, moving -0.13% from the previous trading session.

Kinjel Shah headshot

3 Key Takeaways From J&J's (JNJ) Q2 Earnings Announcement

Here are some of the highlights of J&J's (JNJ) second-quarter earnings call.

Teva Pharmaceutical Industries Ltd. (TEVA) Dips More Than Broader Markets: What You Should Know

Teva Pharmaceutical Industries Ltd. (TEVA) closed at $8.11 in the latest trading session, marking a -1.1% move from the prior day.

Teva Shares Fall Further as Morgan Stanley Downgrades Rating

Shares of Teva (TEVA) are on a downtrend on the risk of high litigation costs related to opioid epidemic in the United States. Morgan Stanley downgrades its rating on Teva.

J&J (JNJ) Beats on Q2 Earnings, Ups 2019 Sales Growth View

J&J (JNJ) beats estimates for both earnings and sales in the second quarter of 2019 and raises 2019 guidance for operational sales growth for the second time this year.

Amneal (AMRX) Down on Guidance Update & Restructuring Plan

Amneal (AMRX) slumps on news of budget cut and reduction in annual guidance.

Court Ruling Topples Trump Order, No Price Display in TV Ads

The recent ruling by a federal court against the Trump regime's decree to disclose the price labels of drugs in TV adverts resumes the spotlight on drug pricing.

Jazz (JAZZ) Acquires Early-Stage Precision Oncology Asset

Jazz (JAZZ) acquired Redx Pharma's early stage pan-RAF inhibitor program for developing potential treatment for cancer with RAF and RAS mutations.

Teva Pharmaceutical Industries Ltd. (TEVA) Outpaces Stock Market Gains: What You Should Know

Teva Pharmaceutical Industries Ltd. (TEVA) closed at $9.43 in the latest trading session, marking a +1.18% move from the prior day.

Regeneron/Sanofi's Libtayo Gets EU Approval for Skin Cancer

Regeneron (REGN) wins approval for skin cancer drug, Libtayo, in the European Union.

AstraZeneca Gets CHMP Nod for Forxiga/Fasenra Expanded Label

AstraZeneca (AZN) gets positive CHMP opinion for self-administration option for Fasenra and the Fasenra pen and to include outcomes data on Forxiga???s label.

Teva Pharmaceutical Industries Ltd. (TEVA) Gains As Market Dips: What You Should Know

Teva Pharmaceutical Industries Ltd. (TEVA) closed at $8.89 in the latest trading session, marking a +0.91% move from the prior day.

Allergan's Botox Wins FDA Nod for Upper Limb Spasticity in Kids

Allergan's (AGN) Botox gets FDA approval for the 10th therapeutic indication, upper limb spasticity in pediatric patients, in the age group of 2 to 17 years.

Teva Pharmaceutical Industries Ltd. (TEVA) Stock Sinks As Market Gains: What You Should Know

Teva Pharmaceutical Industries Ltd. (TEVA) closed at $8.12 in the latest trading session, marking a -0.73% move from the prior day.

Jazz's (JAZZ) New Sleep Drug Sunosi Gets Schedule IV Status

Jazz Pharmaceuticals' (JAZZ) recently approved sleep drug, Sunosi, receives schedule IV designation under controlled substance list from the Drug Enforcement Agency.

Teva Pharmaceutical Industries Ltd. (TEVA) Stock Sinks As Market Gains: What You Should Know

Teva Pharmaceutical Industries Ltd. (TEVA) closed at $8.62 in the latest trading session, marking a -1.03% move from the prior day.

Teva Pharmaceutical Industries Ltd. (TEVA) Stock Sinks As Market Gains: What You Should Know

Teva Pharmaceutical Industries Ltd. (TEVA) closed at $9.26 in the latest trading session, marking a -1.59% move from the prior day.

Celgene's Filing for Ozanimod Accepted for Review in US/EU

The FDA and the EMA accept Celgene's (CELG) multiple sclerosis candidate, ozanimod, for review.

Lilly's Emgality Gets FDA Approval for Cluster Headache

Lilly's (LLY) CGRP antibody, Emgality, becomes the first and only medicine approved to treat episodic cluster headache in adults.

Biogen Reports Interim Phase III Data on Diroximel Fumarate

Biogen (BIIB) announces new interim results from phase III EVOLVE-MS-1 study, which showed that the diroximel fumarate was generally well tolerated in people with relapsing MS.

Lilly In-Licenses Private Biotech's Non-Opoid Pain Candidate

Lilly (LLY) inks a deal with the privately held Centrexion Therapeutics to add the latter's early-stage pain candidate, CNTX-0290, to its portfolio.